A phase II study for anaplastic thyroid cancer

A phase II study for anaplastic thyroid cancer - A phase II study for anaplastic thyroid cancer

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000482

Enrollment

Registered

2006-09-01

Start date

2006-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anaplastic thyroid cancer

Interventions

docetaxelat 60 mg/m2 The interval is 3 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The eligibility criteria are pathologically proven anaplastic thyroid cancer;age, equal or more than 20 years old; at least one measureable lesion; adequate bone marrow, liver, and renal function; performance status of 0 to 2; no previous chemotherapy; written informed consent is required

Exclusion criteria

Exclusion criteria: heavy thoracic, abdominal, or pericardial dropsy; heavy complications such as myocarial infarction, heat failure, cerebral infarctio within 6 months; uncontrolled diabetes; uncontrolled hypertension;symptomatic brain metastases;

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
The median survival and side effects	—

Countries

Japan

Contacts

Public ContactKenji Kawada

Nagoya university hospital Clinical oncology and chemotherapy

052-744-1903

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026